Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 7.37B | 7.31B | 7.43B | 7.56B | 7.88B | 6.43B |
Gross Profit | 3.29B | 3.23B | 3.24B | 3.25B | 3.85B | 3.10B |
EBITDA | 1.56B | 1.62B | 1.64B | 1.61B | 2.17B | 2.08B |
Net Income | 728.00M | 798.00M | 878.00M | 800.00M | 1.33B | 844.00M |
Balance Sheet | ||||||
Total Assets | 4.81B | 4.87B | 5.46B | 5.49B | 6.03B | 11.57B |
Cash, Cash Equivalents and Short-Term Investments | 364.00M | 674.00M | 1.08B | 1.23B | 1.98B | 3.57B |
Total Debt | 4.99B | 4.96B | 5.57B | 6.05B | 6.01B | 7.48B |
Total Liabilities | 6.36B | 6.25B | 7.09B | 7.70B | 7.54B | 12.23B |
Stockholders Equity | -1.55B | -1.39B | -1.63B | -2.21B | -1.52B | -662.00M |
Cash Flow | ||||||
Free Cash Flow | 783.00M | 660.00M | 656.00M | 816.00M | 1.22B | 1.81B |
Operating Cash Flow | 1.00B | 886.00M | 954.00M | 1.14B | 1.49B | 2.04B |
Investing Cash Flow | -217.00M | -162.00M | -286.00M | -328.00M | -259.00M | -219.00M |
Financing Cash Flow | -934.00M | -1.13B | -815.00M | -1.56B | -3.19B | 610.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | 23.71B | 20.27 | 46.14% | ― | 2.94% | 4.57% | |
79 Outperform | 9.31B | 9.96 | 19.36% | 2.54% | -5.24% | -12.89% | |
77 Outperform | 7.69B | 23.48 | 25.38% | 2.46% | 10.93% | -10.83% | |
70 Outperform | 15.66B | 20.40 | 28.65% | 5.09% | -2.21% | -37.30% | |
63 Neutral | $5.46B | 7.87 | -52.83% | 3.11% | -0.18% | -18.95% | |
59 Neutral | 6.01B | 48.48 | -14.58% | ― | 2.38% | -38.88% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
On August 28, 2025, Bath & Body Works reported its second quarter financial results, showing a 1.5% increase in net sales to $1.5 billion. The company adjusted its full-year earnings guidance, raising the low end of its adjusted earnings per share forecast. The company is focusing on strategic moves to enhance digital experiences, product efficacy, and distribution expansion, aiming for durable long-term growth. Despite a decrease in earnings per diluted share compared to the previous year, the company remains optimistic about its growth prospects.